Search - tctmd.com

Displaying 1 - 20 of 106

Sort: Relevancy | Date

ENGULF Novel PE Thrombectomy Device Minimizes Blood Loss

News Conference News VIVA 2025

ENGULF Novel PE Thrombectomy Device Minimizes Blood Loss

November 07, 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

News Conference News TCT 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

October 27, 2025

Renewed Questions About Safety of Paclitaxel Devices in PAD: SWEDEPAD

News Conference News ESC 2025

Renewed Questions About Safety of Paclitaxel Devices in PAD: SWEDEPAD

September 05, 2025

Stroke Risk Higher With TAVI vs Surgery at 5 Years: UK TAVI

News Conference News EuroPCR 2025

Stroke Risk Higher With TAVI vs Surgery at 5 Years: UK TAVI

Michael O'Riordan

May 23, 2025

Meta-analysis Quashes Hopes for Routine Embolic Protection in TAVI

News Conference News EuroPCR 2025

Meta-analysis Quashes Hopes for Routine Embolic Protection in TAVI

Michael O'Riordan

May 21, 2025

Cost Surprises and Delayed Care in Women: BASIL-2 and BEST-CLI

News Conference News CX Symposium 2025

Cost Surprises and Delayed Care in Women: BASIL-2 and BEST-CLI

April 30, 2025

Plant-Derived Compound Shows Early Promise for Small AAAs

News Conference News CX Symposium 2025

Plant-Derived Compound Shows Early Promise for Small AAAs

April 25, 2025

Bioresorbable Scaffold for CLTI Appears to Be an Economical Option: LIFE-BTK

News Conference News CX Symposium 2025

Bioresorbable Scaffold for CLTI Appears to Be an Economical Option: LIFE-BTK

April 24, 2025

Paclitaxel or Sirolimus: New PAD Studies Shed Light on Choices

News Conference News CX Symposium 2025

Paclitaxel or Sirolimus: New PAD Studies Shed Light on Choices

April 23, 2025

Live Valve Cases Safe, With Outcomes Comparable to Trials and Practice

News Conference News PCR London Valves 2024

Live Valve Cases Safe, With Outcomes Comparable to Trials and Practice

Michael O'Riordan

November 25, 2024

DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years

News Conference News VIVA 2024

DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years

November 11, 2024

Amputations Still Avoided With Flow-Diverting Therapy for CLTI at 2 Years: PROMISE II

News Conference News VIVA 2024

Amputations Still Avoided With Flow-Diverting Therapy for CLTI at 2 Years: PROMISE II

November 06, 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

News Conference News VIVA 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

November 05, 2024

PAD Patients’ Views on Decisions and Outcomes Hinge on Sex, Race/Ethnicity: ELEGANCE

News Conference News TCT 2024

PAD Patients’ Views on Decisions and Outcomes Hinge on Sex, Race/Ethnicity: ELEGANCE

November 04, 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

News Conference News TCT 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

October 29, 2024

New ESC Guidelines Merge PAD, Aortic Diseases Into Single Document

News Conference News ESC 2024

New ESC Guidelines Merge PAD, Aortic Diseases Into Single Document

September 10, 2024

No Sex-Specific Differences in PAD Therapy Outcomes: REVIVE Analysis

News Conference News SCAI 2024

No Sex-Specific Differences in PAD Therapy Outcomes: REVIVE Analysis

May 10, 2024

Women, Black Patients Less Likely to Get Advanced PE Therapy, Analysis Shows

News Conference News SCAI 2024

Women, Black Patients Less Likely to Get Advanced PE Therapy, Analysis Shows

May 06, 2024

CALORI: More Support for Eschewing Fasting Protocols Preprocedure

News Conference News SCAI 2024

CALORI: More Support for Eschewing Fasting Protocols Preprocedure

May 02, 2024

Interatrial Shunt Falls Short in Sham-Controlled RELIEVE-HF

News Conference News ACC 2024

Interatrial Shunt Falls Short in Sham-Controlled RELIEVE-HF

Michael O'Riordan

April 06, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.